145 related articles for article (PubMed ID: 37425738)
1. Acquired Cross-resistance in Small Cell Lung Cancer due to Extrachromosomal DNA Amplification of
Choudhuri SP; Girard L; Lim JYS; Wise JF; Freitas B; Yang D; Wong E; Hamilton S; Chien VD; Gilbreath C; Zhong J; Phat S; Myers DT; Christensen CL; Stanzione M; Wong KK; Farago AF; Meador CB; Dyson NJ; Lawrence MS; Wu S; Drapkin BJ
bioRxiv; 2023 Jun; ():. PubMed ID: 37425738
[TBL] [Abstract][Full Text] [Related]
2. Acquired Cross-Resistance in Small Cell Lung Cancer due to Extrachromosomal DNA Amplification of MYC Paralogs.
Pal Choudhuri S; Girard L; Lim JYS; Wise JF; Freitas B; Yang D; Wong E; Hamilton S; Chien VD; Kim YJ; Gilbreath C; Zhong J; Phat S; Myers DT; Christensen CL; Mazloom-Farsibaf H; Stanzione M; Wong KK; Hung YP; Farago AF; Meador CB; Dyson NJ; Lawrence MS; Wu S; Drapkin BJ
Cancer Discov; 2024 May; 14(5):804-827. PubMed ID: 38386926
[TBL] [Abstract][Full Text] [Related]
3. Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and Is Associated with Worse Outcomes.
Pongor LS; Schultz CW; Rinaldi L; Wangsa D; Redon CE; Takahashi N; Fialkoff G; Desai P; Zhang Y; Burkett S; Hermoni N; Vilk N; Gutin J; Gergely R; Zhao Y; Nichols S; Vilimas R; Sciuto L; Graham C; Caravaca JM; Turan S; Tsai-Wei S; Rajapakse VN; Kumar R; Upadhyay D; Kumar S; Kim YS; Roper N; Tran B; Hewitt SM; Kleiner DE; Aladjem MI; Friedman N; Hager GL; Pommier Y; Ried T; Thomas A
Cancer Discov; 2023 Apr; 13(4):928-949. PubMed ID: 36715552
[TBL] [Abstract][Full Text] [Related]
4. Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer.
Owonikoko TK; Zhang G; Kim HS; Stinson RM; Bechara R; Zhang C; Chen Z; Saba NF; Pakkala S; Pillai R; Deng X; Sun SY; Rossi MR; Sica GL; Ramalingam SS; Khuri FR
J Transl Med; 2016 May; 14(1):111. PubMed ID: 27142472
[TBL] [Abstract][Full Text] [Related]
5. Blocking Genomic Instability Prevents Acquired Resistance to MAPK Inhibitor Therapy in Melanoma.
Dharanipragada P; Zhang X; Liu S; Lomeli SH; Hong A; Wang Y; Yang Z; Lo KZ; Vega-Crespo A; Ribas A; Moschos SJ; Moriceau G; Lo RS
Cancer Discov; 2023 Apr; 13(4):880-909. PubMed ID: 36700848
[TBL] [Abstract][Full Text] [Related]
6. Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts.
Drapkin BJ; George J; Christensen CL; Mino-Kenudson M; Dries R; Sundaresan T; Phat S; Myers DT; Zhong J; Igo P; Hazar-Rethinam MH; Licausi JA; Gomez-Caraballo M; Kem M; Jani KN; Azimi R; Abedpour N; Menon R; Lakis S; Heist RS; Büttner R; Haas S; Sequist LV; Shaw AT; Wong KK; Hata AN; Toner M; Maheswaran S; Haber DA; Peifer M; Dyson N; Thomas RK; Farago AF
Cancer Discov; 2018 May; 8(5):600-615. PubMed ID: 29483136
[TBL] [Abstract][Full Text] [Related]
7. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
Ma L; Bian X; Lin W
J Exp Clin Cancer Res; 2020 Oct; 39(1):219. PubMed ID: 33069237
[TBL] [Abstract][Full Text] [Related]
8. MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat.
Chen J; Guanizo AC; Jakasekara WSN; Inampudi C; Luong Q; Garama DJ; Alamgeer M; Thakur N; DeVeer M; Ganju V; Watkins DN; Cain JE; Gough DJ
J Exp Clin Cancer Res; 2023 Apr; 42(1):100. PubMed ID: 37098540
[TBL] [Abstract][Full Text] [Related]
9. Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer.
Farago AF; Yeap BY; Stanzione M; Hung YP; Heist RS; Marcoux JP; Zhong J; Rangachari D; Barbie DA; Phat S; Myers DT; Morris R; Kem M; Dubash TD; Kennedy EA; Digumarthy SR; Sequist LV; Hata AN; Maheswaran S; Haber DA; Lawrence MS; Shaw AT; Mino-Kenudson M; Dyson NJ; Drapkin BJ
Cancer Discov; 2019 Oct; 9(10):1372-1387. PubMed ID: 31416802
[TBL] [Abstract][Full Text] [Related]
10. The
Bian X; Wang X; Zhang Q; Ma L; Cao G; Xu A; Han J; Huang J; Lin W
Front Oncol; 2020; 10():565820. PubMed ID: 33134168
[TBL] [Abstract][Full Text] [Related]
11. Role of mTOR As an Essential Kinase in SCLC.
Kern JA; Kim J; Foster DG; Mishra R; Gardner EE; Poirier JT; Rivard C; Yu H; Finigan JH; Dowlati A; Rudin CM; Tan AC
J Thorac Oncol; 2020 Sep; 15(9):1522-1534. PubMed ID: 32599072
[TBL] [Abstract][Full Text] [Related]
12. Targeting the Ubiquitin-Proteasome System Using the UBA1 Inhibitor TAK-243 is a Potential Therapeutic Strategy for Small-Cell Lung Cancer.
Majeed S; Aparnathi MK; Nixon KCJ; Venkatasubramanian V; Rahman F; Song L; Weiss J; Barayan R; Sugumar V; Barghout SH; Pearson JD; Bremner R; Schimmer AD; Tsao MS; Liu G; Lok BH
Clin Cancer Res; 2022 May; 28(9):1966-1978. PubMed ID: 35165102
[TBL] [Abstract][Full Text] [Related]
13. [Establishment of A Patient-derived Xenotransplantation Animal Model for Small Cell Lung Cancer and Drug Resistance Model].
Zhu Y; Huang W; Wu Y; Jia L; Li Y; Chen R; Guo L; Chen Q
Zhongguo Fei Ai Za Zhi; 2019 Jan; 22(1):6-14. PubMed ID: 30674387
[TBL] [Abstract][Full Text] [Related]
14. Clinical relevance of human cancer xenografts as a tool for preclinical assessment: example of in-vivo evaluation of topotecan-based chemotherapy in a panel of human small-cell lung cancer xenografts.
Némati F; Daniel C; Arvelo F; Legrier ME; Froget B; Livartowski A; Assayag F; Bourgeois Y; Poupon MF; Decaudin D
Anticancer Drugs; 2010 Jan; 21(1):25-32. PubMed ID: 19823076
[TBL] [Abstract][Full Text] [Related]
15. Targeted profiling of human extrachromosomal DNA by CRISPR-CATCH.
Hung KL; Luebeck J; Dehkordi SR; Colón CI; Li R; Wong IT; Coruh C; Dharanipragada P; Lomeli SH; Weiser NE; Moriceau G; Zhang X; Bailey C; Houlahan KE; Yang W; González RC; Swanton C; Curtis C; Jamal-Hanjani M; Henssen AG; Law JA; Greenleaf WJ; Lo RS; Mischel PS; Bafna V; Chang HY
Nat Genet; 2022 Nov; 54(11):1746-1754. PubMed ID: 36253572
[TBL] [Abstract][Full Text] [Related]
16.
Grunblatt E; Wu N; Zhang H; Liu X; Norton JP; Ohol Y; Leger P; Hiatt JB; Eastwood EC; Thomas R; Ibrahim AH; Jia D; Basom R; Eaton KD; Martins R; Houghton AM; MacPherson D
Genes Dev; 2020 Sep; 34(17-18):1210-1226. PubMed ID: 32820040
[TBL] [Abstract][Full Text] [Related]
17. Translesion DNA synthesis mediates acquired resistance to olaparib plus temozolomide in small cell lung cancer.
Stanzione M; Zhong J; Wong E; LaSalle TJ; Wise JF; Simoneau A; Myers DT; Phat S; Sade-Feldman M; Lawrence MS; Hadden MK; Zou L; Farago AF; Dyson NJ; Drapkin BJ
Sci Adv; 2022 May; 8(19):eabn1229. PubMed ID: 35559669
[TBL] [Abstract][Full Text] [Related]
18. In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin.
Jensen PB; Holm B; Sorensen M; Christensen IJ; Sehested M
Br J Cancer; 1997; 75(6):869-77. PubMed ID: 9062409
[TBL] [Abstract][Full Text] [Related]
19. MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion.
Chalishazar MD; Wait SJ; Huang F; Ireland AS; Mukhopadhyay A; Lee Y; Schuman SS; Guthrie MR; Berrett KC; Vahrenkamp JM; Hu Z; Kudla M; Modzelewska K; Wang G; Ingolia NT; Gertz J; Lum DH; Cosulich SC; Bomalaski JS; DeBerardinis RJ; Oliver TG
Clin Cancer Res; 2019 Aug; 25(16):5107-5121. PubMed ID: 31164374
[TBL] [Abstract][Full Text] [Related]
20. Case report: TP53 and RB1 loss may facilitate the transformation from lung adenocarcinoma to small cell lung cancer by expressing neuroendocrine markers.
Li J; Wei B; Feng J; Wu X; Chang Y; Wang Y; Yang X; Zhang H; Han S; Zhang C; Zheng J; Groen HJM; van den Berg A; Ma J; Li H; Guo Y
Front Endocrinol (Lausanne); 2022; 13():1006480. PubMed ID: 36583000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
